Development of a new UPLC-MSMS method for the determination of temozolomide in mice: Application to plasma pharmacokinetics and brain distribution study

Biomedical Chromatography

Volumn 27, Issue 7, 2013, Pages 889-893

  Goldwirt, Lauriane ^a   Zahr, Noel ^b   Farinotti, Robert ^a   Fernandez, Christine ^a  

^a EA4123   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Brain distribution; LC MS MS; Mice; Pharmacokinetics; Temozolomide

Indexed keywords

LIQUID CHROMATOGRAPHY; MAMMALS; MASS SPECTROMETRY;

BRAIN DISTRIBUTION; INTERNAL STANDARDS; LC-MS-MS; LC.MS/MS; LIMIT OF QUANTIFICATIONS; MICE PLASMA; MOUSE; MOUSE BRAIN; SINGLE-STEP; TEMOZOLOMIDE;

PHARMACOKINETICS;

TEMOZOLOMIDE; THEOPHYLLINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG ISOLATION; DRUG STABILITY; FEMALE; LIMIT OF QUANTITATION; MASS SPECTROMETRY; MOUSE; NONHUMAN; SENSITIVITY ANALYSIS; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VALIDATION PROCESS;

MUS;

EID: 84878969919     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.2877     Document Type: Article

References (14)

1. Andrasi M, Törzsök B et al. Determination of temozolomide in serum and brain tumor with micellar electrokinetic capillary chromatography. Journal of Chromatography B 2011; 879(23): 2229-2233.
2. D'Atri S, Tentori L et al. Involvement of the mismatch repair system in temozolomide-induced apoptosis. Molecular Pharmacology 1998; 54(2): 334-341.
3. Denny BJ, Wheelhouse RT et al. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 1994; 33(31): 9045-9051.
4. Diez B, Statkevich P et al. Evaluation of the exposure equivalence of oral versus intravenous temozolomide. Cancer Chemotherapy and Pharmacology 2010; 65(4): 727-734.
5. EMEA. Assessment Report for Temozolomide Teva, 2010.
6. FDA. FDA Guidance for Industry: Bioanalytical Method Validation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research: Rockville, MD, 2001.
7. Goldwirt L, Lemaitre F et al. A new UPLC-MS/MS method for the determination of irinotecan and 7-ethyl-10-hydroxycamptothecin (SN-38) in mice: application to plasma and brain pharmacokinetics. Journal of Pharmaceutical and Biomedical Analysis 2012; 66: 325-333.
8. Kim H, Likhari P et al. High-performance liquid chromatographic analysis and stability of anti-tumor agent temozolomide in human plasma. Journal of Pharmaceutical and Biomedical Analysis 2001; 24(3): 461-468.
9. Newlands ES, Stevens MFG et al. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treatment Reviews 1997; 23(1): 35-61.
10. Patel M, McCully C et al. Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates. Journal of Neuro-Oncology 2003; 61(3): 203-207.
11. Reyderman L, Statkevich P et al. Disposition and pharmacokinetics of temozolomide in rat. Xenobiotica 2004; 34(5): 487-500.
12. Shah VP, Midha KK et al. Bioanalytical method validation - a revisit with a decade of progress. Pharmaceutical Research 2000; 17(12): 1551-1557.
13. Shen F, Decosterd LA et al. Determination of temozolomide in human plasma and urine by high-performance liquid chromatography after solid-phase extraction. Journal of Chromatography B: Biomedical Sciences and Applications 1995; 667(2): 291-300.
14. Stupp R, Mason WP et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England Journal of Medicine 2005; 352(10): 987-996.